Motoko Saito-Yabe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Motoko Saito-Yabe has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
A Kurihara
Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd., Hiromachi, Shinagawa-ku, Tokyo, Japan, and
1 shared publicationAkiko Okada
Biological Research Laboratories III, Daiichi Sankyo Co., Ltd. , Tokyo
1 shared publicationAtsushi Kurihara
Drug Metabolism and Pharmacokinetics Research Laboratories, Daiichi Sankyo Co., Ltd. , Tokyo
1 shared publicationEisuke Tsuda
Biological Research Laboratories III, Daiichi Sankyo Co., Ltd. , Tokyo
1 shared publicationFumihiko Okada
Biological Research Laboratories III, Daiichi Sankyo Co., Ltd. , Tokyo
1 shared publicationJuergen Mueller
Drug Metabolism Department, Daiichi Sankyo Europe GmbH , Martinsried
1 shared publication
Latest Publications
- 21 July 2010
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 62 (8) , 985-994
PEGylation of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) results in decreased uptake into rats and human liver
Objectives Our aim was to investigate the effect of PEGylation on the uptake of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) into rat liver, kidney and spleen, and human liver. Methods Copolymer of polyethyleneglycol allylmethylether and maleamic acid sodium salt with OCIF (poly(PEG)‐OCIF) (0.5 mg/kg) was administered to rats and the concentrations of poly(PEG)‐OCIF in the liver, kidney and spleen at 15 min after administration were measured by ELISA. For human liver uptake, the liver perfusion of OCIF and 3H‐labelled poly(PEG)‐OCIF was conducted using fresh human liver block. Key findings The tissue uptake of poly(PEG)‐OCIF in rats was significantly lower compared with that of OCIF. In fresh human liver perfusion, 3H‐poly(PEG)‐OCIF was rarely taken up into the liver. On the other hand, more than 50% of the perfused OCIF was taken up. Conclusions PEGylation of OCIF using poly(PEG) dramatically suppressed the uptake of OCIF into human liver as well as into rat liver and could be a promising approach for improving the pharmacokinetic and pharmacological effects of OCIF in the clinical setting.
- 21 July 2010
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 62 (8) , 985-994
PEGylation of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) results in decreased uptake into rats and human liver
Objectives Our aim was to investigate the effect of PEGylation on the uptake of osteoprotegerin/osteoclastogenesis inhibitory factor (OPG/OCIF) into rat liver, kidney and spleen, and human liver. Methods Copolymer of polyethyleneglycol allylmethylether and maleamic acid sodium salt with OCIF (poly(PEG)‐OCIF) (0.5 mg/kg) was administered to rats and the concentrations of poly(PEG)‐OCIF in the liver, kidney and spleen at 15 min after administration were measured by ELISA. For human liver uptake, the liver perfusion of OCIF and 3H‐labelled poly(PEG)‐OCIF was conducted using fresh human liver block. Key findings The tissue uptake of poly(PEG)‐OCIF in rats was significantly lower compared with that of OCIF. In fresh human liver perfusion, 3H‐poly(PEG)‐OCIF was rarely taken up into the liver. On the other hand, more than 50% of the perfused OCIF was taken up. Conclusions PEGylation of OCIF using poly(PEG) dramatically suppressed the uptake of OCIF into human liver as well as into rat liver and could be a promising approach for improving the pharmacokinetic and pharmacological effects of OCIF in the clinical setting.
- Open Access
- 28 August 2009
- Published by Wiley in British Journal of Pharmacology
- Vol. 158 (2) , 548-557
Highly frequent anti‐idiotype antibody in cynomolgus monkeys developed against mouse‐derived regions of anti‐Fas antibody humanized by complementarity determining region grafting
Background and purpose: We investigated the immunogenicity of a humanized anti‐human Fas monoclonal antibody, R‐125224, in cynomolgus monkeys to estimate its efficacy, as well as its toxicity in clinical situations.Experimental approach: R‐125224 was intravenously administered to cynomolgus monkeys at single doses of 0.4, 1.2, 6 and 30 mg·kg−1, and the plasma concentrations of R‐125224 and anti‐R‐125224 antibody (ARA) were measured. We conducted a competitive enzyme‐linked immunosorbent assay to determine which part of R‐125224 was recognized by ARA. We also examined the retention of radioactivity in mononuclear cells and granulocytes after the injection of [125I]‐R‐125224 to a collagen‐induced arthritis monkey model.Key results: After i.v. administration of R‐125224, the elimination of the plasma R‐125224 concentrations was accelerated at around 10 days post‐dose, and 10 of 12 monkeys were ARA positive. From an epitope analysis of ARA, the ARA produced in monkeys recognized the mouse‐derived regions located in complementarity determining regions, but could not recognize the human IgG. After the injection of [125I]‐R‐125224 to a collagen‐induced arthritis monkey model, a significantly longer retention of the radioactivity in mononuclear cells compared to granulocytes was observed.Conclusions and implications: In monkeys, the development of antibodies against R‐125224 is rapid and highly frequent. Our hypothesis is that this highly frequent development of ARA might be due to the binding of R‐125224 to immune cells, and its circulation in monkey blood might contribute to an increase in its chances of being recognized as an immunogen.
- 28 August 2009
- Published by Wiley in British Journal of Pharmacology
- Vol. 158 (2) , 548-557
Open AccessHighly frequent anti‐idiotype antibody in cynomolgus monkeys developed against mouse‐derived regions of anti‐Fas antibody humanized by complementarity determining region grafting
Background and purpose: We investigated the immunogenicity of a humanized anti‐human Fas monoclonal antibody, R‐125224, in cynomolgus monkeys to estimate its efficacy, as well as its toxicity in clinical situations.Experimental approach: R‐125224 was intravenously administered to cynomolgus monkeys at single doses of 0.4, 1.2, 6 and 30 mg·kg−1, and the plasma concentrations of R‐125224 and anti‐R‐125224 antibody (ARA) were measured. We conducted a competitive enzyme‐linked immunosorbent assay to determine which part of R‐125224 was recognized by ARA. We also examined the retention of radioactivity in mononuclear cells and granulocytes after the injection of [125I]‐R‐125224 to a collagen‐induced arthritis monkey model.Key results: After i.v. administration of R‐125224, the elimination of the plasma R‐125224 concentrations was accelerated at around 10 days post‐dose, and 10 of 12 monkeys were ARA positive. From an epitope analysis of ARA, the ARA produced in monkeys recognized the mouse‐derived regions located in complementarity determining regions, but could not recognize the human IgG. After the injection of [125I]‐R‐125224 to a collagen‐induced arthritis monkey model, a significantly longer retention of the radioactivity in mononuclear cells compared to granulocytes was observed.Conclusions and implications: In monkeys, the development of antibodies against R‐125224 is rapid and highly frequent. Our hypothesis is that this highly frequent development of ARA might be due to the binding of R‐125224 to immune cells, and its circulation in monkey blood might contribute to an increase in its chances of being recognized as an immunogen.